HOME >> MEDICINE >> NEWS
Studies indicate medication can be an effective therapy for smoking cessation

The drug varenicline shows effectiveness in helping smokers quit and abstain from smoking when compared to placebo and the smoking cessation medication bupropion, according to three studies in the July 5 issue of JAMA.

Although nearly 41 percent of smokers try to quit smoking each year, relapse is common, and only about 10 percent achieve and maintain abstinence. The negative effects of nicotine withdrawal account, in part, for low success rates, according to background information in the article. Approved pharmacotherapies to treat nicotine dependence (e.g., nicotine replacement therapy and bupropion) have had important, but moderate efficacy, with reported rates of quitting generally twice those of placebo. Additional and more effective therapies are needed.

David Gonzales, Ph.D., of Oregon Health & Science University, Portland, and colleagues with the Varenicline Phase 3 Study Group evaluated the efficacy of varenicline compared with placebo and sustained-release (SR) bupropion in generally healthy adult smokers. Varenicline is a non-nicotine drug that is thought to be beneficial for smoking cessation by stimulating the release of the chemical dopamine in the brain to reduce craving and withdrawal while simultaneously blocking the reinforcing effects of smoked nicotine. Most other smoking cessation pharmacotherapies are nicotine replacement products.

Participants in the study were 1,025 smokers (10 cigarettes or more per day) with fewer than 3 months of smoking abstinence in the past year. The randomized, double-blind, phase 3 clinical trial was conducted at 19 U.S. centers from June 2003 to April 2005. Participants were randomly assigned to receive brief counseling plus either varenicline twice per day (n = 352), bupropion SR twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up.

The carbon monoxideconfirmed 4-week continuous abstinence rate for weeks 9 th
'"/>

Contact: Tamara Hargens
503-494-8231
JAMA and Archives Journals
4-Jul-2006


Page: 1 2 3 4 5 6 7

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies suggest investigational agent reduces disease activity in MS
4. Studies highlight advances in diagnosis, medical therapy
5. Studies highlight real world use, safety of drug-eluting stents
6. Studies led by Rhode Island Hospital confirm safety and efficacy
7. Studies identify food sources of disease and drug resistance
8. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
9. Studies highlight need to monitor heart function in breast cancer patients
10. Studies examine physician disclosure of medical errors
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
(Date:11/24/2014)... November 24, 2014 Abington Health ... MD has joined The Neurology Group and has ... Sclerosis Center. , A graduate of Vinnica Medical ... at Albert Einstein Medical Center in Philadelphia and completed ... Multiple Sclerosis Center at Weill Cornell Medical College. Ternopolska ...
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier and leader in ... Evening Dresses. All these fresh items are offered at ... the special offer is valid until Dec. 20, 2014. ... been working well in the fashion industry for years. ... new dresses may be the best products for many ...
(Date:11/24/2014)... The typical American diet includes foods that are ... a diet high in calories and carbohydrates only enables ... typically accumulate around the internal organs exposing people to ... the form of love handles, beer bellies and thunder ... rid themselves of the burden of embarrassing, unhealthy and ...
(Date:11/24/2014)... Dr. Michael Kettel , a leading fertility ... NBC to discuss egg freezing as a viable and increasingly ... the news recently, with new company benefits at Facebook and ... , “[The companies] see it as a way to take ... path.” Says Dr. Kettel. , Up until a few weeks ...
(Date:11/23/2014)... For the coming special Friday, Tidebuy, a ... great promotion for many products, especially the beautiful colored ... best choice with amazing discounts, up to 90% off. ... It is easy to buy colored wedding dresses in ... is also famous for delicate craftsmanship, elegant style and ...
Breaking Medicine News(10 mins):Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2
(Date:11/24/2014)... CHICAGO , Nov. 24, 2014 The ... will host an investor conference call to discuss its ... ended September 30, 2014 on Tuesday, December 2, 2014 ... expects to report its operating results earlier the same ... participate in the conference call by dialing 1-877-374-8416 (international ...
(Date:11/24/2014)...  Surgical Theater LLC ha annunciato oggi ... l,apertura in data 24 novembre del primo ... IRCCS Istituto Neurologico Nazionale "C. Besta". I ... pianificazione chirurgica) e Surgical Navigation Advanced Platform ... presentati in occasione dell,evento dedicato alle loro ...
(Date:11/22/2014)... Nov. 22, 2014  Sprout Pharmaceuticals today announced positive preliminary ... women treated with flibanserin up to 200 mg at bedtime ... presented at the 20 th Annual Fall Scientific Meeting ... in Miami . ... the Complete Response Letter and the Formal Dispute Resolution that ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 2La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 3La tecnologia di Surgical Theater in mostra in Italia all'apertura del centro Besta NeuroSim di Milano 4Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3
Cached News: